<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName journalpublishing.dtd?>
  <?SourceDTD.Version 2.3?>
  <?ConverterInfo.XSLTName jp2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nucleosides Nucleotides Nucleic Acids</journal-id>
      <journal-id journal-id-type="publisher-id">lncn</journal-id>
      <journal-title-group>
        <journal-title>Nucleosides, Nucleotides &amp; Nucleic Acids</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1525-7770</issn>
      <issn pub-type="epub">1532-2335</issn>
      <publisher>
        <publisher-name>Taylor &amp; Francis</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3024846</article-id>
      <article-id pub-id-type="pmid">21128175</article-id>
      <article-id pub-id-type="doi">10.1080/15257770.2010.535803</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Simple and Rapid Enzymatic Method for the Synthesis of Single-Strand Oligonucleotides Containing Trifluorothymidine</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Suzuki</surname>
            <given-names>Norihiko</given-names>
          </name>
          <xref ref-type="corresp" rid="COR1"/>
          <xref ref-type="aff" rid="A1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fukushima</surname>
            <given-names>Masakazu</given-names>
          </name>
          <xref ref-type="aff" rid="A1">
            <sup>1</sup>
          </xref>
        </contrib>
        <aff id="A1"><label>1</label>Tokushima Research Center, Taiho Pharmaceutical Co., Ltd., Kawauchi, Tokushima, Japan</aff>
      </contrib-group>
      <author-notes>
        <corresp id="COR1">Address correspondence to Norihiko Suzuki, Tokushima Research Center, Taiho Pharmaceutical Co., Ltd., 224-2 Hiraishi-ebisuno, Kawauchi, Tokushima 771-0194, Japan. E-mail: <email>suzuki@taiho.co.jp</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>11</month>
        <year>2010</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <season>Nov&#x2013;Dec</season>
        <year>2010</year>
      </pub-date>
      <volume>29</volume>
      <issue>11-12</issue>
      <fpage>896</fpage>
      <lpage>904</lpage>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>8</month>
          <year>2010</year>
        </date>
        <date date-type="rev-recd">
          <day>26</day>
          <month>8</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>10</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2010 Taylor &amp; Francis</copyright-statement>
        <copyright-year>2010</copyright-year>
        <license license-type="open-access" xlink:href="http://www.informaworld.com/mpp/uploads/iopenaccess_tcs.pdf">
          <license-p>This is an open access article distributed under the <ext-link ext-link-type="uri" xlink:href="http://www.informaworld.com/mpp/uploads/iopenaccess_tcs.pdf">Supplemental Terms and Conditions for iOpenAccess articles published in Taylor &amp; Francis journals</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>To investigate the mechanism of trifluorothymidine (TFT)-induced DNA damage, we developed an enzymatic method for the synthesis of single-strand oligonucleotides containing TFT-monophosphate residues. Sixteen-mer oligonucleotides and 14-mer 5&#x2032;-phosphorylated oligonucleotides were annealed to the template of 25-mer, so as to empty one nucleotide site. TFT-triphosphate was incorporated into the site by DNA polymerase and then ligated to 5&#x2032;-phosphorylated oligonucleotides by DNA ligase. The synthesized 31-mer oligonucleotides containing TFT residues were isolated from the 25-mer complementary template by denaturing polyacrylamide electrophoresis. Using these single-strand oligonucleotides containing TFT residues, the cleavage of TFT residues from DNA, using mismatch uracil-DNA glycosylase (MUG) of E.coli origin, was compared with that of 5-fluorouracil (5FU) and 5-bromodeoxyuridine (BrdU). The TFT/A pair was not cleaved by MUG, while the other pairs, namely, 5FU/A, 5FU/G, BrdU/A, BrdU/G, and TFT/G, were easily cleaved from each synthesized DNA. Thus, this method is useful for obtaining some site-specifically modified oligonucleotides.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>TFT</kwd>
        <kwd>trifluorothymidine</kwd>
        <kwd>5-trifluormethyl-2&#x2032;-deoxyuridine</kwd>
        <kwd>5-fluorouracil 5-fluoro-2&#x2032;-deoxyuridine</kwd>
        <kwd>oligonucleotide</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>INTRODUCTION</title>
      <p>Trifluorothymidine (TFT), which is a component of the oral drug formulation TAS-102, is known to inhibit thymidylate synthase and to be incorporated into the DNA, similar to 5-fluorouracil (5FU) or 5-fluoro-2&#x2032;-deoxyuridine (FdUrd).</p>
      <p>The efficacy of TAS-102 as an oral chemotherapeutic agent for metastatic gastrointestinal cancer is currently under investigation in phase I/II clinical trials.<sup>[<xref ref-type="bibr" rid="R1">1</xref>]</sup> We demonstrated that short-term high-dose exposure to TFT increased its incorporation into DNA and resulted in potent antitumor activity against human cancer cells, both those sensitive and resistant to 5FU.<sup>[<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R3">3</xref>]</sup> Therefore, it is necessary to investigate the mode of action of TFT against DNA replication and repair enzymes, as compared with that of 5FU and FdUrd. The incorporation of commercially available TFT into DNA using phosphoramidite chemistry<sup>[<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R5">5</xref>]</sup> has been reported. However, after a trityl-on oligonucleotide was synthesized in the solid phase, the trifluoromethyl at the 5-position in the base converted to nitrile under the standard deprotection condition (concd NH<sub>4</sub>OH at 55&#xB0;C for 16 hours)<sup>[<xref ref-type="bibr" rid="R6">6</xref>].</sup> These results indicated that the conversion was due to the known reactivity and instability of the trifluoromethyl group of 5-trifluoromethyluracil toward nucleophiles under basic conditions. Holzberger et al.<sup>[<xref ref-type="bibr" rid="R7">7</xref>]</sup> reported that when trifluorothymidine triphosphate (TFT-TP) was synthesized, its nucleotide could be incorporated into the DNA by some DNA polymerases. In order to examine the mode of action of several analogues incorporated into the DNA, it is necessary to use single-strand oligonucleotide site-specific incorporation of these analogues. Therefore, the present study describes the establishment of a method for the generation of single-strand oligonucleotides containing TFT residues for investigating of the effect of TFT against DNA repair and replication enzymes.</p>
    </sec>
    <sec sec-type="materials|methods" id="s2">
      <title>MATERIALS AND METHODS</title>
      <sec id="s3">
        <title>Reagents</title>
        <p>5-Trifluorothymidine-5&#x2032;-triphosphate (TFT-TP) was synthesized by contract research with Moravek Biochemical Inc. (USA). [Gamma-<sup>32</sup>P] adenosine 5&#x2032;-triphosphate, tetra (triethylammonium) salt (111 TBq/mmol, NEG502A) was purchased from Perkin Elmer Company (USA).</p>
      </sec>
      <sec id="s4">
        <title>Enzymes and Oligonucleotides</title>
        <p>Sequenase, a version 2.0 DNA polymerase was purchased from USB Corporation (USA). Pfu DNA polymerase was purchased from Fermentas life Sciences (USA). Klenow fragment (3&#x2032; &#x2192; 5&#x2032; exonuclease minus and 5&#x2032; &#x2192; 3&#x2032; exonuclease minus) was purchased from New England BioLabs (USA). mismatch uracil-DNA glycosylase (MUG) was purchased from Trevigen Inc. (USA). Oligonucleotides containing 5FU, BrdU, U, and other normal bases were purchased from Sigma Chemical Co., as gel-purified grade chemicals (Japan).</p>
      </sec>
      <sec id="s5">
        <title>Primer Extension Assay</title>
        <p>The 17-base primer was labeled with <sup>32</sup>P at its 5&#x2032;-end and annealed to its complementary M13mp18(+) DNA template.</p>
        <disp-quote>
          <p>(5&#x2032;) <sup>32</sup>P-GTAAAACGACGGCCAGT</p>
          <p>(3&#x2032;) CATTTTGCTGCCGGTCACGGTTCGAACGTACGGACGT</p>
        </disp-quote>
        <p>The DNA primer extension assay<sup>[<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9">9</xref>]</sup> was carried out in a total volume of 10 <italic>&#xB5;</italic>L, containing 2.5 pmole primer/template, DNA polymerase, and dNTP mixture (containing or not containing FTP-triphosphate), at 37&#xB0;C for 30 minutes. The reaction was stopped by adding 3.3 <italic>&#xB5;</italic>L denaturing loading buffer (95% formamide/10 mM EDTA/0.1%BPB/0.1%XC). The mixture was boiled at 100&#xB0;C for 3 minutes and cooled on ice. The electrophoresis and the subsequent analysis was performed using the BAS2000 system.</p>
      </sec>
      <sec id="s6">
        <title>Synthesis of Oligonucleotides Containing TFT</title>
        <p>A 16-mer oligonucleotide (DNA(a)) and 14-mer 5&#x2032;-phosphorylated oligonucleotide (DNA(b)) were annealed with a 25-mer oligonucleotide (DNA(c)) as the template as described below.</p>
        <disp-quote>
          <p>DNA(a); 5&#x2032;-GACTAGTCTGCATGCC-3&#x2032;</p>
          <p>DNA(b); 5&#x2032; P-ACGTACGTTGCATG-3&#x2032;</p>
          <p>DNA(c); 5&#x2032;-GCAACGTACGTAGGCATGCAGACTA-3&#x2032;</p>
        </disp-quote>
        <p>The reaction mixture (2.26 mL) containing 30 nmol of DNA(a), 40 nmol of DNA(b), 40 nmol of DNA(c), 2 &#x3BC;mol of TFT triphosphate (TFT-TP), and 800 U of sequenase in 20 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub> and 25 mM NaCl was incubated at 37&#xB0;C for 30 minutes; then, 200&#x3BC;L of T4 DNA ligase (Nippon Gene Co., Ltd., Japan) and 280&#x3BC; of 10 x ligation buffer (500 mM Tris-HCl, 100 mM MgCl<sub>2</sub>, 200 mM DTT, and 10 mM ATP) were added to the mixture. The reactions were allowed to proceed for 30 minutes at room temperature. The reaction products were concentrated by the addition of butanol and precipitated by ethanol. The DNA crude solution was purified by electrophoresis on 15% polyacrylamide gels containing TBE buffer (100 mM Tris.pH 8.3, 100 mM borate, 2 mM EDTA, 8M urea).</p>
      </sec>
      <sec id="s7">
        <title>Analysis of Oligonucleotides Containing TFT</title>
        <p>The purity of the modified synthetic DNA fragments was checked by polyacrylamide gel electrophoresis and HPLC.</p>
        <p>To cleave the phosphodiester bonds, DNA was treated with 5 units of nuclease P1 (Sigma-Aldrich Corp., USA) in 0.05 mM Tris-HCl, pH 6.0, in the presence of 0.5 mM NaCl at 37&#xB0;C for 1 hour. And then the reaction mixture was treated with alkaline phosphatase (Takara, Japan) in 0.1 mM Tris-HCl, pH 8.0, 0.25 mM NaCl, 1 mM MgCl<sub>2</sub> at 37&#xB0;C for 1 hour. With this treatment, all the nucleotides were dephosphorylated to nucleosides. The resolved nucleosides were analyzed using an HPLC system (Gulliver HPLC system, Jasco Co., Ltd., Japan).</p>
      </sec>
      <sec id="s8">
        <title>DNA Glycosylase Assay</title>
        <p>Oligomers (31-mer) containing a TFT-monophosphate or other deoxyribonucleotide were labeled with <sup>32</sup>P at their 5&#x2032;-end and annealed to their complementary 31-base templates. The DNA glycosylase assay<sup>[<xref ref-type="bibr" rid="R10">10</xref>]</sup> was carried out in a total volume of 10&#x3BC;L containing 2.5 pmole primer/template, mismatch uracil-DNA glycosylase (MUG) in 20 mmol/L Tris, 1 mmol/L EDTA, and 50 mmol/L NaCl, the reactions being allowed to proceed at 37&#xB0; C for 60 minutes. The reactions were stopped, followed by treatment with 100 mM NaOH at 90&#xB0;C for 15 minutes, in order to cleave the sugar-phosphate backbone at the AP site. The labeled oligonucleotides were precipitated with 3 times their volumes of ethanol at 80&#xB0;C for 10 hours and dissolved in 10&#x3BC;L of 50 mM Tris (pH 8.0) and 5 mM MgCl<sub>2</sub>. This sample was added to 3.3&#x3BC;L of the denaturing loading buffer (95% formamide/10 mM EDTA/0.1%BPB/0.1%XC), boiled at 100&#xB0;C for 3 minutes, and then cooled on ice. The reaction products were separated by 15% polyacrylamide sequencing gel electrophoresis and analyzed using the BAS20000 system.</p>
        <p>A 31-mer <sup>32</sup>P labeled drug-containing or normal oligomer (DNA(1)) and 31-mer oligomer (DNA(2) or DNA(3)) were also prepared:</p>
        <disp-quote>
          <p>DNA(1); &#x2217;5&#x2032;-GACTAGTCTGCATGCCXACGTACGTTGCATG-3&#x2032;</p>
          <p>where X is U, T(DNA(1)[T]), TFT(DNA(1)[TFT]), 5BrU or 5FU.</p>
          <p>DNA(2); 5&#x2032;-CATGCAACGTACGTAGGCATGCAGACTAGTC -3&#x2032;</p>
          <p>DNA(3); 5&#x2032;-CATGCAACGTACGTGGGCATGCAGACTAGTC -3&#x2032;</p>
        </disp-quote>
      </sec>
      <sec id="s9">
        <title>Electrophoresis and Autoradiography</title>
        <p>Products from the DNA synthesis and ligation reactions were analyzed by electrophoresis on 15% polyacrylamide gels containing TBE buffer (100 mM Tris.pH 8.3, 100 mM borate, 2 mM EDTA, 8 M urea) at 1500V for 23 hours.</p>
        <p>Autoradiography was performed for 210 hours using the Fujix BAS 2000 system (Fuji Photo-Film, Tokyo, Japan).</p>
      </sec>
    </sec>
    <sec sec-type="results" id="s10">
      <title>RESULTS</title>
      <sec id="s11">
        <title>Analysis of Synthesized TFT-Containing Oligonucleotide</title>
        <p>The synthesized trifluorothymidine-triphosphate (TFT-TP) was analyzed by mass spectrometry (<xref ref-type="fig" rid="F1">Figure 1</xref>). TFT-TP was detected as the peak corresponding to 535.16 m/z.</p>
      </sec>
      <sec id="s12">
        <title>Incorporation TFT into DNA by Several DNA Polymerases</title>
        <p>DNA primer extension assay was used to measure the activity of the incorporated TFT-TP into DNA by several commercial available DNA polymerases (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
        <fig id="F1" position="float">
          <label>FIGURE 1</label>
          <caption>
            <p>Mass spectrum of TFT-TP. Mass-analysis was performed using an ESI source in negative mode. The acquired m/z was from 435.00 to 635.00. The ionization parameters were capillary voltage, &#x2212;47.5V; source voltage, 3.02 kV; capillary temperature, 233.50&#xB0;C.</p>
          </caption>
          <graphic xlink:href="lncn29-893_f1"/>
        </fig>
        <fig id="F2" position="float">
          <label>FIGURE 2</label>
          <caption>
            <p>Incorporation TFT into DNA by several DNA polymerases. Actions of TFT and BrdU on DNA primer extension in vitro. The ability of pfu DNA polymerase (pfu, 2.5 U/10&#x3BC;), Sequenase DNA polymerase (Sequenase, 13 U/10&#x3BC;), and Klenow fragment DNA polymerase (Klenow, 2.0 U/10&#x3BC;) to extend the 5&#x2032;-<sup>32</sup>P-labeled primer/M13mp19(+) DNA (5 &#x3BC;g/mL) was evaluated in the presence of dATP, dGTP, and dCTP with or without dTTP, with TFT-TP, and with BrdUTP. Lanes 14, dideoxynucleotide sequencing of the M13mp19(+) DNA template with ddGTP, ddATP, ddTTP, and ddCTP, respectively, are indicated.</p>
          </caption>
          <graphic xlink:href="lncn29-893_f2"/>
        </fig>
        <p>When dTTP was omitted from the mixture (T-reaction), the primer was elongated by sequenase DNA polymerase and klenow fragment DNA polymerase, which paused at the T site, but not by pfu DNA polymerase (<xref ref-type="fig" rid="F2">Figure 2</xref>, lanes 5, 10, and 13). These results suggest the error-prone property of these enzymes.<sup>[<xref ref-type="bibr" rid="R11">11</xref>]</sup> Sequenase DNA polymerase and klenow fragment DNA polymerase were able to incorporate TFT-TP into DNA, but pfu DNA polymerase showed little activity in this situation.</p>
      </sec>
      <sec id="s13">
        <title>Enzymatic Synthesis of Oligonucleotides Containing TFT</title>
        <p>In order to investigate the actions of TFT on the DNA replication and repair enzymes, 31-mer oligonucleotides containing TFT were synthesized enzymatically (<xref ref-type="fig" rid="F3">Figure 3</xref>). First, for the DNA polymerase reaction step, we used sequenase DNA polymerase, as shown in <xref ref-type="fig" rid="F2">Figure 2</xref>. TFT-TP was completely incorporated into the nucleotide site (T-site) between the 16-mer oligonucleotides and 5&#x2032;-phosphorylated 14-mer oligonucleotides within 10 minutes. This reaction does not allow elongation of more than one nucleotide site, because the pre-annealed 5&#x2032;-phosphorylated 14-mer oligonucleotides hinder the next elongation.</p>
        <p>Second, in the DNA ligase reaction step, if TFT were not incorporated into the T-site or were incorporated in more than one nucleotide site, then DNA ligase would not be able to connect its oligomers with the 5&#x2032;-phosphorylated 14-mer oligonucleotides. Therefore, the synthesized 31-mer oligomer appears to be site-specifically incorporated into the TFT-monophosphate residues.</p>
        <p>Third, we purified these oligonucleotides by denaturing polyacrylamide electrophoresis. At this step, we did not use ethidium bromide to stain the DNA, because the band of the 31-mer oligomer was immediately detected by direct UV irradiation from a UV lamp.</p>
        <fig id="F3" position="float">
          <label>FIGURE 3</label>
          <caption>
            <p>Enzymatic reaction of DNA polymerase and DNA ligase. Sixteen-mer oligonucleotides were labeled with <sup>32</sup>P and aliquots (0.05 &#x3BC;L) were added to the reaction mixture for monitoring the enzymatic reaction. Except adding the <sup>32</sup>P labeled oligonucleotides, the same experiments were performed as described in synthesis oligonucleotides containing TFT section of Materials and Methods).</p>
          </caption>
          <graphic xlink:href="lncn29-893_f3"/>
        </fig>
        <fig id="F4" position="float">
          <label>FIGURE 4</label>
          <caption>
            <p>Analysis of oligonucleotide containing TFT using high-performance liquid chromatography. Oligonucleotides containing TFT were resolved into nucleosides by the treatment with phosphodiesterase and alkaline phosphatase as described in Material and Methods. Aliquots (50 &#x3BC;L) of the treated samples were applied to a Chemcosorb 300-5C18 column (4.6 i.d. &#xD7; 250 mm, Chemco Corp., Ltd.) under the following chromatographic conditions: mobile phase, 2% acetonitrile containing 0.01% trifluoroacetic acid; flow rate, 1.ml/min;monitoring wavelength, 254 nm.</p>
          </caption>
          <graphic xlink:href="lncn29-893_f4"/>
        </fig>
      </sec>
      <sec id="s14">
        <title>Analysis of the Synthesized Oligonucleotides Containing TFT</title>
        <p>The oligonucleotides were digested by nuclease P1 and alkaline phosphatase and were confirmed to show the TFT peak in the HPLC (<xref ref-type="fig" rid="F4">Figure 4</xref>).</p>
      </sec>
      <sec id="s15">
        <title>Excision Activity by E. coli Mismatch Uracil-DNA Glycosylase of TFT-Containing Oligonucleotides</title>
        <p>In order to investigate the cleavage activity of TFT residues by E. coli mismatch uracil-DNA glycosylase (MUG), single-strand oligonucleotides containing TFT monophosphate residues and complementary oligonucleotides (TFT/A pair or TFT/G pair) were prepared (<xref ref-type="fig" rid="F5">Figure 5</xref>). MUG (4 unit) excised not only the U/G pair, but also the U/A pair following incubation at 37&#xB0;C for 1 hour. These results were consistent with a previous report.<sup>[<xref ref-type="bibr" rid="R12">12</xref>]</sup> Under these conditions, all of the 5FU/A, 5FU/G, and BrdU/G, BrdU/A, and TFT/G pairs were removed, but not the TFT/A pair. These studies indicate that MUG does not have the ability to recognize and remove TFT paired to adenine in the double-strand DNA.</p>
        <fig id="F5" position="float">
          <label>FIGURE 5</label>
          <caption>
            <p>Cleavage by E. coli mismatch uracil-DNA glycosylase (MUG) of oligonucleotides containing several 5-substituted pyrimidine nucleotide residues. Lanes 15 show cleavage of a double-strand oligonucleotide with several 5-substituted pyrimidine nucleotide residues paired to the adenine base, and lanes 610 show the same sequence with the analogues paired to the guanine base. The oligonulcleotides (0.125 pmol/&#x3BC;l) were incubated with 4.0 units of MUG at 37&#xB0;C for 60 minutes.</p>
          </caption>
          <graphic xlink:href="lncn29-893_f5"/>
        </fig>
      </sec>
    </sec>
    <sec sec-type="discussion" id="s16">
      <title>DISCUSSION</title>
      <p>5-Fluorouracil (5FU) an antitumor pyrimidine, has been widely used for the treatment of gastric, colorectal, head and neck and breast cancers. Like 5FU, TFT is believed to exert its cytocidal effect by inhibiting TS.<sup>[<xref ref-type="bibr" rid="R13">13</xref>]</sup> However, we found that when tumors were exposed to high concentrations of TFT for short periods of time, the drug was incorporated into the DNA and exerted its cytocidal activity by causing DNA fragmentation rather than by inhibiting TS.<sup>[<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R14">14</xref>]</sup> Therefore, we considered it necessary to prepare oligonucleotides to investigate with the mode of action of trifluorothymidine (TFT) against DNA replication and repair enzymes as compared to 5FU.</p>
      <p>We succeeded in synthesizing single-strand oligonucleotides containing TFT-monophosphate residues using DNA polymerase and DNA ligase, but failed to synthesize these oligonucleotides using the principle of phosphoramidite chemistry<sup>[<xref ref-type="bibr" rid="R6">6</xref>]</sup> (data not shown). We used a simple and rapid method in the present study, making use of enzymatic reactions under physiological conditions.</p>
      <p>E. coli mismatch uracil-DNA glycosylase (MUG) can remove 5FU/A, 5FU/G, and 5-bromodeoxyuridine (BrdU)/G, BrdU/A, and TFT/G pairs, but not the TFT/A pair.</p>
      <p>MUG belongs to family 2 of the uracil-DNA glycosylase superfamily.<sup>[<xref ref-type="bibr" rid="R15">15</xref>]</sup> Thymine DNA glycosylase (TDG) also belongs to the same family. This family of MUG and TDG displays quite distinct properties, being insensitive to inhibition by UGI and inactive on ss-uracil-DNA, and lacking the conserved catalytic residues and specificity determinants of the Family-1 UDGs.<sup>[<xref ref-type="bibr" rid="R16">16</xref>]</sup></p>
      <p>When TFT is mispaired with guanine, MUG is able to excise the TFT from the DNA, similar to BrdU and 5FU. Unlike BrdU and 5FU, however, MUG was not able to recognize and remove TFT paired to adenine in the double-strand DNA.</p>
      <p>In vivo or ex vivo experiments using live cell cultures are very important, and we plan to continue studying this mechanism. We believe that investigation of the reactivity of several analogues incorporated into the DNA with other DNA repair enzymes is a useful approach to identify new therapeutic targets.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Overman</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Kopetz</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Varadhachary</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Fukushima</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kuwata</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Mita</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wolff</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Hoff</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Abbruzzese</surname>
              <given-names>J.L.</given-names>
            </name>
          </person-group>
          <article-title>Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors</article-title>
          <source>Cancer Invest.</source>
          <year>2008</year>
          <volume>2008</volume>
          <fpage>794</fpage>
          <lpage>799</lpage>
          <pub-id pub-id-type="pmid">18798063</pub-id>
        </element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murakami</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Kazuno</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Emura</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Tsujimoto</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Fukushima</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells</article-title>
          <source>Int. J. Oncol.</source>
          <year>2000</year>
          <volume>2000</volume>
          <fpage>277</fpage>
          <lpage>283</lpage>
          <pub-id pub-id-type="pmid">10891536</pub-id>
        </element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emura</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ohshimo</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Fukushima</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA</article-title>
          <source>Int. J. Oncol.</source>
          <year>2004</year>
          <volume>2004</volume>
          <fpage>571</fpage>
          <lpage>578</lpage>
          <pub-id pub-id-type="pmid">15289858</pub-id>
        </element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gmeiner</surname>
              <given-names>W.H.</given-names>
            </name>
            <name>
              <surname>Pon</surname>
              <given-names>R.T.</given-names>
            </name>
            <name>
              <surname>Lown</surname>
              <given-names>J.W.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis, annealing properties, fluorine-19 NMR characterization, and detection limits of a trifluorothymidine-labeled antisense oligodeoxyribonucleotide 21 mer</article-title>
          <source>J. Org. Chem.</source>
          <year>1991</year>
          <volume>1991</volume>
          <fpage>3602</fpage>
          <lpage>3608</lpage>
        </element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cook</surname>
              <given-names>P.D.</given-names>
            </name>
            <name>
              <surname>Sanghvi</surname>
              <given-names>Y.S.</given-names>
            </name>
          </person-group>
          <article-title>Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression</article-title>
          <source>Chem. Abstr.</source>
          <year>1992</year>
          <volume>1992</volume>
          <fpage>111996</fpage>
          <comment>US Patent 5,614,617, 1992</comment>
        </element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Markley</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Chirakul</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Sologub</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Sigurdsson</surname>
              <given-names>S.T.</given-names>
            </name>
          </person-group>
          <article-title>Incorporation of 2&#x2032;-deoxy-5-(trifluoromethyl)uridine and 5-Cyano-2&#x2032;-deoxyuridine into DNA</article-title>
          <source>Bioorg. Med. Chem. Lett.</source>
          <year>2001</year>
          <volume>2001</volume>
          <fpage>2453</fpage>
          <lpage>2455</lpage>
          <pub-id pub-id-type="pmid">11549445</pub-id>
        </element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holzberger</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Marx</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Enzymatic synthesis of perfluoroalkylated DNA</article-title>
          <source>Bioorgan. Med. Chem.</source>
          <year>2009</year>
          <volume>2009</volume>
          <fpage>3653</fpage>
          <lpage>3658</lpage>
        </element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mikita</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Beardsley</surname>
              <given-names>G.P.</given-names>
            </name>
          </person-group>
          <article-title>Functional consequences of the arabinosylcytosine structural lesion in DNA</article-title>
          <source>Biochemistry</source>
          <year>1988</year>
          <volume>1988</volume>
          <fpage>4698</fpage>
          <lpage>4705</lpage>
          <pub-id pub-id-type="pmid">2458756</pub-id>
        </element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Chubb</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hertel</surname>
              <given-names>L.W.</given-names>
            </name>
            <name>
              <surname>Grindey</surname>
              <given-names>G.B.</given-names>
            </name>
            <name>
              <surname>Plunkett</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Action of 2&#x2032;,2&#x2032;-difluorodeoxycytidine on DNA synthesis</article-title>
          <source>Cancer Res.</source>
          <year>1991</year>
          <volume>1991</volume>
          <fpage>6110</fpage>
          <lpage>6117</lpage>
          <pub-id pub-id-type="pmid">1718594</pub-id>
        </element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neddermann</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Jiricny</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>The purification of a mismatch-specific thymine-DNA glycosylase from HeLa cells</article-title>
          <source>J. Biol. Chem.</source>
          <year>1993</year>
          <volume>1993</volume>
          <fpage>21218</fpage>
          <lpage>21224</lpage>
          <pub-id pub-id-type="pmid">8407958</pub-id>
        </element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kunkel</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Sabatino</surname>
              <given-names>R.D.</given-names>
            </name>
            <name>
              <surname>Bambara</surname>
              <given-names>R.A.</given-names>
            </name>
          </person-group>
          <article-title>Exonucleolytic proofreading by calf thymus DNA polymerase delta</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>1987</year>
          <volume>1987</volume>
          <fpage>4865</fpage>
          <lpage>4869</lpage>
          <pub-id pub-id-type="pmid">3474631</pub-id>
        </element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Theruvathu</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Darwanto</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lao</surname>
              <given-names>V.V.</given-names>
            </name>
            <name>
              <surname>Pascal</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Goddard</surname>
              <given-names>W.</given-names>
              <suffix>3rd.</suffix>
            </name>
            <name>
              <surname>Sowers</surname>
              <given-names>L.C.</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of base selection by the Escherichia coli mispaired uracil glycosylase</article-title>
          <source>J. Biol. Chem.</source>
          <year>2008</year>
          <volume>2008</volume>
          <fpage>8829</fpage>
          <lpage>8836</lpage>
          <pub-id pub-id-type="pmid">18208817</pub-id>
        </element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peters</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>van der Wilt</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>van Triest</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Codacci-Pisanelli</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>P.G.</given-names>
            </name>
            <name>
              <surname>van Groeningen</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Pinedo</surname>
              <given-names>H.M.</given-names>
            </name>
          </person-group>
          <article-title>Thymidylate synthase and drug resistance</article-title>
          <source>Eur. J. Cancer</source>
          <volume>1995</volume>
          <issue>31A</issue>
          <fpage>1299</fpage>
          <lpage>1305</lpage>
        </element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emura</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Nakagawa</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Fujioka</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ohshimo</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yokogawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Okabe</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kitazato</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA</article-title>
          <source>Int. J. Mol. Med.</source>
          <year>2004</year>
          <volume>2004</volume>
          <fpage>249</fpage>
          <lpage>255</lpage>
          <pub-id pub-id-type="pmid">14719131</pub-id>
        </element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pearl</surname>
              <given-names>L.H.</given-names>
            </name>
          </person-group>
          <article-title>Structure and function in the uracil-DNA glycosylase superfamily</article-title>
          <source>Mutat. Res.</source>
          <year>2000</year>
          <volume>2000</volume>
          <fpage>165</fpage>
          <lpage>181</lpage>
          <pub-id pub-id-type="pmid">10946227</pub-id>
        </element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barrett</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Savva</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Panayotou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Barlow</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Jiricny</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Pearl</surname>
              <given-names>LH</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of a G:T/U mismatch-specific DNA glycosylase: mismatch recognition by complementary-strand interactions</article-title>
          <source>Cell</source>
          <year>1998</year>
          <volume>1998</volume>
          <fpage>117</fpage>
          <lpage>129</lpage>
          <pub-id pub-id-type="pmid">9489705</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
